Diabetes Information

FDA Approves NovoLog(R) Labeling Update
Diabetes patients taking NovoLog((R)) (insulin aspart [rDNA origin] injection) can now use the insulin in their pump for up to six days following the U.S. Food and Drug Administration (FDA) approval of a labeling change, diabetes care company Novo Nordisk announced today.(1) The previous label allowed for NovoLog((R)) to be stored in the pump reservoir for two days. This makes NovoLog((R)) the first and only rapid-acting insulin with this extended in-use time.